Aprea Therapeutics Acquires Atrin Pharmaceuticals

XenoTherapeutics / Xeno Acquisition Corp Acquire Repare Therapeutics

January 28, 2026

Biotechnology

Repare Therapeutics has been acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) pursuant to a statutory plan of arrangement. Under the transaction, Repare shareholders received approximately US$2.20 per share plus one contingent value right (CVR) per share; the deal was approved by shareholders and the Superior Court of Québec and will result in Repare’s delisting and suspension of public reporting.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Recipharm Acquires Arranta Bio

February 18, 2022

Biotechnology

Recipharm has acquired Arranta Bio, a US-based CDMO specializing in advanced therapy medicinal products (ATMPs), microbiome therapeutics and mRNA manufacturing, to expand its biologics and ATMP capabilities and establish a stronger US presence. Arranta Bio brings fermentation, purification, analytics and end-to-end mRNA drug substance and drug product capabilities; the transaction was expected to close around the end of March 2022.

Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.

February 3, 2026

Pharmaceuticals

Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.

APNAR Pharma Acquires Aurex Laboratories

February 3, 2022

Pharmaceuticals

APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.